LYON, France & NEW YORK--(BUSINESS WIRE)--The MEDICREA group (Paris:ALMED) (Alternext Paris: FR0004178572 - ALMED), a PEA-PME eligible company specializing in the development and manufacturing of innovative surgical technologies for the treatment of spinal pathologies, pursuant to the authorization granted by the Extraordinary Shareholders Meeting of June 3rd, 2015, announces the successful completion of a capital increase of 3.5 million euros (share premium included) via a private placement. This capital raise was authorized and approved by MEDICREA’s Board of Directors on June 3rd, 2015. The terms of the private placement are detailed below.
Characteristics of the issue:
- Issuance of 485,438 new shares at a price of 7.30 euros per share, which corresponds to the weighted average share price over the 3 trading sessions preceding the Board’s authorization and approval of the capital raise on June 3rd, 2015, less a 0.8% discount
- Preferential subscription rights waived in favor of qualified investors and a limited number of investors in the sense of article L411-2 of the French Monetary and Financial Code, as amended by order n° 2009-80 of January 22nd, 2009
- The number of shares outstanding following this transaction is 8,987,588
Purpose of the issue:
The proceeds from this issue will be used to:
1/ further strengthen MEDICREA’s commercial presence in the United States in order to accelerate market penetration in this key region, which now accounts for approximately 60% of the Company’s sales;
2/ establish a new marketing subsidiary in Germany, Europe’s largest spine surgery market; operational from July 2015;
3/ rebalance the Group’s financial structure (financial debt over shareholders’ equity) following the substantial investments in industrial equipment and material carried out over the last 6 months.
Several long-standing investors, as well as Denys SOURNAC, founder, Chairman and CEO of MEDICREA, participated in the private placement.
In accordance with article 211-3 of the AMF’s general regulations, this transaction did not require a prospectus to be submitted to the AMF in order to obtain a visa.
ABOUT MEDICREA (www.medicrea.com)
The MEDICREA Group specializes in the design, manufacture, and distribution of innovative proprietary technologies devoted exclusively to spinal surgery. Operating in a $10 billion market, MEDICREA is a small to medium-sized business with 140 employees, including 40 at its MEDICREA USA Corp. subsidiary based in New York City.
The Company enjoys an excellent and ever-improving reputation, and develops unique scientific partnerships with some of the most visionary and creative spine surgeons in France, the UK, and the USA. The products developed and patented by MEDICREA provide neurosurgeons and orthopedic surgeons specializing in the spine with new and less-invasive surgical solutions that are faster and easier to implement than traditional techniques.
MEDICREA has also become a pioneer and global leader in the manufacturing of customized implants for personalized spinal surgery with the development of a comprehensive process incorporating the software analysis of each patient, the pre-surgical planning of the surgical strategy, and the production of customized spinal osteosynthesis rods (UNiD™ rod) and lumbar interbody osteosynthesis cages (UNiD™ ALIF cage) that are made to measure by a 3D printer.
The Group’s headquarters are based near Lyon, France. It also has an implant and surgical instrument manufacturing facility located in La Rochelle, France, as well as four distribution subsidiaries in the USA, the UK, France and Germany.
MEDICREA is listed on ALTERNEXT Paris
ISIN: FR 0004178572 – Ticker: ALMED
Denys Sournac, Tél : +33 (0)4 72 01 87 87
Chairman and Chief Executive Officer
Fabrice Kilfiger, Tél : +33 (0)4 72 01 87 87
Chief Financial Officer
Financial Communication / Press and Investor Relations
Sophie Boulila / Pierre Laurent
Tel: +33 (0)1 44 71 94 91
Published at Business Wire